Treatment beyond four cycles of first line Platinum and Etoposide chemotherapy in real-life patients with stage IV Small Cell Lung Cancer: a retrospective study of the Merseyside and Cheshire Cancer network

Treatment beyond four cycles of first line Platinum and Etoposide chemotherapy in real-life patients with stage IV Small Cell Lung Cancer: a retrospective study of the Merseyside and Cheshire Cancer network

Abstract Background Dose intensity and dose density of first line Platinum and Etoposide (PE) do not influence Overall Survival (OS) of Small Cell Lung Cancer (SCLC) patients. The effect of treatment length, however, remains unclear. Current guidelines recommend treating beyond 4 cycles -up to 6-, i...

Full description

Bibliographic Details
Main Authors: Mostafa Sallam, Helen Wong, Carles Escriu
Format: Article
Language:English
Published: BMC 2019-11-01
Series:BMC Pulmonary Medicine
Subjects:
Lung neoplasm
Small cell lung carcinoma
Drug therapy
Observational study
Antineoplastic combined chemotherapy protocols
Online Access:http://link.springer.com/article/10.1186/s12890-019-0948-x

Similar Items

Similar Items